Reliability of Community Ambulation Ability, Fall Risk, and Dynamic Visual Acuity Assessments in Stroke

March 20, 2026 updated by: Yea-Ru Yang, National Yang Ming Chiao Tung University

Reliability of Community Ambulation Assessments, Taiwan Chinese Version of Falls Efficacy Scale, and Dynamic Visual Acuity Test in Individuals With Chronic Stroke

Nearly half of individuals with stroke experience limitations in community ambulation, and 35.7% of community-dwelling stroke survivors experienced falls while walking, indicating that falls are common during routine daily activities in community settings. Patla (1999) proposed that community mobility is influenced by eight factors: ambient conditions, terrain characteristics, external physical load, attentional demands, postural transitions, traffic level, time constraints, and walking distance. This framework suggests that community ambulation requires consideration of multiple physiological domains as well as environmental factors. However, current assessments of community ambulation primarily rely on indoor walking speed as an indicator, which may be insufficient to fully evaluate patients' community ambulation ability. Previous studies have not yet established the reliability of community ambulation assessments such as the Walking Ability Questionnaire, community walking speed, and the Falls Efficacy Scale (Taiwan Chinese version)-in individuals with chronic stroke. Additionally, stroke survivors often demonstrate insufficient integration of vestibular information, which may affect gait performance through impaired dynamic visual acuity. Therefore, this study aims to investigate the reliability of community ambulation assessments and dynamic visual acuity testing in individuals with chronic stroke.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Taiwan
      • Taipei, Taiwan, 112
        • Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Individuals with chronic stroke

Description

Inclusion Criteria:

  • Diagnosis of First-occurrenced stroke
  • ≥ 6 months after stroke
  • Ability to walk at least 400 meters with or without the use of a walking assistive device
  • Mini-Mental State Examination score ≥ 24
  • Age between 18 and 80 years

Exclusion Criteria:

  • Other neurological or musculoskeletal conditions affected postural stability
  • Presence of dizziness or vertigo
  • Presence of conditions affecting cervical blood flow or limiting cervical range of motion
  • Visual impairment
  • Unstable cardiac status or uncontrolled hypertension

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Walking Ability Questionnaire
Time Frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Walking Ability Questionnaire consisting of 19 items related to daily walking activities to assess community ambulation
The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Community Walking Speed
Time Frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Participants will complete an approximately 400-meter walking task
The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Taiwan Chinese Version of the Falls Efficacy Scale
Time Frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Participants will rate their level of concern about falling while performing 16 activities using a 4-point Likert scale to evaluate fall risk
The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Dynamic Visual Acuity Test
Time Frame: The test will be conducted twice, with the second session scheduled 3-10 days after the first session
Using Dynamic Visual Acuity Test to evaluate vestibulo-ocular reflex function
The test will be conducted twice, with the second session scheduled 3-10 days after the first session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Yang Ming Chiao Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 31, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 20, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 27, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NYCU114245AF1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings